All News
46 articles in total
Multi-Dimensional Follicle Activation: The Technological Evolution of PHMO's Hair Growth Series
Going beyond mere blockade, PHMO's Hair Growth Promoter series is dedicated to directly awakening the vitality of hair follicles. Our ingredients work synergistically through multiple mechanisms from improving microcirculation to combating fibrosis to create a dynamic growth environment for hair regeneration.
Precision-Targeting Androgenic Alopecia: The Strategy & Breakthrough of PHMO's Anti-Androgen APIs
At PHMO, we are reshaping the fight against androgenetic alopecia with our cutting-edge anti-androgen portfolio. Our ingredients target the root cause—the damaging effects of Dihydrotestosterone (DHT), empowering formulators with diverse solutions from personal care to pharmaceutical grades.
Ultra-High-Purity APIs: Let Your Hair Loss Product Overtake the Competition!
In the field of hair loss products, although minoxidil and finasteride still dominate the mainstream, consumers have turned their attention to a new generation of solutions that are more effective, gentler, and have fewer side effects. PHMO has entered the market with a full line of high-purity active pharmaceutical ingredients (APIs) — ranging from FDA gold-standard classic ingredients to cutting-edge black-tech new molecular entities — providing a one-stop solution to eliminate formulation concerns for brands.
Six Major Innovations in Organic Synthesis in October, Enabling New Breakthroughs in Drug Development
Here are some innovative synthetic chemistry technologies to watch in October, recommended by CRO Charles River.
JACS: A Novel MSH-Based Skeletal Editing Strategy for Pyridine-to-Pyridazine Transformation – Essential Synthetic Insights!
A carbon-to-nitrogen exchange-based skeletal editing method for converting pyridines to pyridazines has been successfully established. This approach employs MSH as the nitrogen source and utilizes mCPBA to promote ring remodeling. It operates under mild conditions, requires no inert atmosphere or light irradiation, and exhibits excellent functional group tolerance. Furthermore, the method has been applied to the late-stage modification of complex drug molecules, serving as a powerful tool for diversifying heterocycle chemistry and advancing drug discovery.
The World's First Dual-load ADC hRS7-E+T (KH815) Preclinical Data Released
Kanghong Pharmaceutical's jointly developed world's first dual-load TROP2-targeted ADC, hRS7-E+T (KH815), published its preclinical results in 《Molecular Cancer Therapeutics》. Its innovative "one antibody, two toxicities" design releases two payloads sequentially, first overcoming drug resistance and then precisely killing the target. In vitro and in vivo experiments (including drug-resistant models) showed superior activity compared to existing ADCs, with an HNSTD of 50 mg/kg. The drug has received clinical trial approvals in China and Australia and is currently initiating international multi-center clinical trials, providing a new solution for tumor drug resistance.